I know that I am still a youngster (as far as PD is concerned), but can some
of you more experienced folks comment on whether there was always "a cure
around the corner". In the last couple of months my news service has
produced about seven stories concerning cures and treatments. Is technology
really improving?
Ron
------------------------------------------------------------------
SIBIA Neurosciences Issued Patent on
Nicotinic Receptor Compound,
SIB-1508Y, and its use in Treating
Parkinson's Disease
Source: PR Newswire
LA JOLLA, Calif., Jan. 22 /PRNewswire/ via Individual Inc. -- SIBIA
Neurosciences, Inc. (Nasdaq-NNM: SIBI) today announced that it has been
issued U.S. Patent No. 5,594,011 on a series of compounds, including its lead
compound SIB-1508Y, that modulate nicotinic acetylcholine receptors. The
patent provides coverage for the composition of the compounds as well as their
use for treating Parkinson's disease.
SIB-1508Y, and the broader series of compounds, represent one of several new
classes of compounds discovered by SIBIA that target specific human receptor
subtypes in the brain. These receptor subtypes modulate communications
between nerve cells and play a key role in a variety of neurological disorders.
SIB-1508Y is selective for certain nicotinic acetylcholine receptor
subtypes that
regulate the release of dopamine and acetylcholine, both relevant in the
deficits
caused by Parkinson's disease. SIBIA plans to commence a Phase I clinical trial
of SIB-1508Y under an Investigational New Drug (IND) application recently filed
with the U.S. Food and Drug Administration (FDA).
Commenting on the patent, William T. Comer, Ph.D., SIBIA president and chief
executive officer stated, "There is a growing body of scientific evidence
establishing the link between certain nicotinic receptors and a variety of
nervous
system disorders, including Parkinson's disease, Alzheimer's disease and
schizophrenia. We believe SIBIA has one of the strongest technology positions
relative to nicotinic receptors and ligands, and the issuance of this
patent further
establishes our proprietary position. With this new patent, we now have
coverage on both the target receptor molecules as well as compounds that
modulate them."
SIBIA Neurosciences, Inc. is engaged in the discovery and development of
novel, small molecule therapeutics for central nervous system disorders
based on
its unique approach to characterizing the molecular processes involved in such
disorders. SIBIA is focusing its efforts on developing compounds for the
treatment of Parkinson's disease, Alzheimer's disease, stroke, head trauma,
epilepsy, chronic pain, schizophrenia and other disorders. The Company
currently has collaborations with Eli Lilly and Company, Ciba (Novartis) and
Bristol-Myers Squibb Company.
This press release contains forward-looking statements that involve risks and
uncertainties. As a result, actual results could differ materially from those
discussed herein. These risks and uncertainties include SIBIA's early stage of
development, the new and uncertain state of SIBIA's technologies, SIBIA's
future capital needs and the uncertainty of receiving additional funding,
uncertainties regarding patents, proprietary rights and regulatory matters, and
other research, development and market risks. These and other risks and
uncertainties are more fully set forth in SIBIA's Prospectus included in its
Registration Statement on Form S-1 filed in connection with its initial public
offering, as well as in SIBIA's most recently filed Form 1O-Q. SOURCE Sibia
Neurosciences Inc.
/CONTACT: Michael J. Dunn, Vice President, Business Development of Sibia
Neurosciences, 619-452-5892/ (SIBI) CO: Sibia Neurosciences Inc. ST: California
IN: MTC SU: TT -- LAW073 -- 0896 01/22/97 16:02 EST
http://www.prnewswire.com
[01-22-97 at 12:00 EST, PR Newswire]
